

Medical Aid-in-Dying Utilization Report



January 2023

Nearly 30 years ago, in November 1994, Oregon passed the nation's first law giving mentally capable, terminally ill adults the end-of-life care option of medical aid in dying to peacefully end unbearable suffering. The law survived legal challenges as well as a repeal measure referred to the ballot by the Oregon Legislature, with 60% of Oregon voters choosing to retain the law. The law was officially implemented in 1997.

Today, more than one in five people — 22% — live in a jurisdiction where medical aid in dying is authorized, either through statute or court decision. This list includes ten states: Oregon (1994, ballot initiative), Washington (2008, ballot initiative), Montana (2009, state Supreme Court decision), Vermont (2013, legislation, amended in 2022), California (2015, legislation, amended in 2021), Colorado (2016, ballot initiative), Hawaii (2018, legislation), New Jersey (2019, legislation), Maine (2019, legislation), New Mexico (2021, legislation) as well as the District of Columbia (2016, legislation).

We no longer have to hypothesize about what will happen if this medical practice is authorized. We now have 25 years of data since Oregon implemented its law in 1997 and years of experience from other authorized jurisdictions, including annual statistical reports from nine jurisdictions. (No Montana data is included in this report since Montana's Supreme Court ruled that no state statute prohibits medical aid in dying, and the court decision did not mandate data collection.) In fact, when California lawmakers reviewed data from the first five years following the End of Life Option Act's implementation, they concluded that the law protects vulnerable populations as intended, but it had too many unnecessary regulatory roadblocks. As a result, California reauthorized and improved its law in 2021. It reduced the 15-day waiting period between the two oral requests for medication to 48 hours so that more eligible dying people would not needlessly suffer, unable to access the law. Based on data from all authorized jurisdictions, New Mexico passed a medical aid-in-dying law in 2021 requiring only one written request for medical aid in dying (no oral requests) and allowing a prescribing clinician to waive the 48-hour waiting period between receiving the written request and filling the medication prescription if the terminally ill person is likely to die during the waiting period. It also followed the standard way medicine is practiced in its jurisdictions and included advanced practice registered nurses (APRNs) and physician assistants as prescribing providers. Finally, Vermont lawmakers updated their law in 2022 to improve access, including eliminating an additional 48-hour waiting period at the end of the request process.

This report is a compilation of annual reports from all of the jurisdictions where medical aid in dying is authorized that collect data. The data clearly demonstrate that concerns of abuse, coercion or misuse are unfounded, and the medical practice provides relief from suffering. Across all the authorized jurisdictions that report data, 6,378 individuals to date have chosen to use medical aid in dying to peacefully end intolerable suffering.

We know that while few people use medical aid in dying, many gain peace of mind and comfort simply knowing the option exists. Further, medical aid in dying creates a shift within our end-of-life care system from a paternalistic model to one that is resoundingly person-driven, which contributes to improvements in hospice, palliative care, and pain and symptom management.

Terminally ill people in jurisdictions that have not authorized medical aid in dying need this option now. We have reassuring data, strong public support and evidence that medical aid in dying is politically viable and desirable. The time has come for compassionate lawmakers in their respective states to listen to the wishes of constituents and authorize medical aid in dying this year.

Sincerely,

Kim Callinan

President and CEO

Compassion & Choices

Kim Callinan

Context and Methods

Currently, nine authorized jurisdictions have issued reports regarding the use of medical-aid-in-dying laws: Oregon,¹ Washington,² Vermont,³ California,⁴ Colorado,⁵ Hawai'i⁶, the District of Columbia⁷, New Jersey⁸ and Maine⁹. In all jurisdictions where medical aid in dying was authorized by legislation or ballot measure, there are statistical reporting requirements for administrative agencies, such as state health departments. However, the reported data is not standardized, and the report formats can change from year to year. In addition, New Mexico has not issued an official report as of this writing, so that data is not included here. Listed below are the data points most useful in demonstrating how medical aid in dying is being used and where there are opportunities to improve access.

- People who received a prescription and people who died after ingestion provide us with two key pieces of information: how many people made it through the entire process to obtain a prescription for medical aid in dying and how many of those individuals decided to take the medication.
- Race, gender and age categories show where disparities exist. Race and ethnicity are not reported universally across jurisdictions, nor are these categories always reflective of the different ways people identify. The inconsistency and limited options for reporting make accurately tracking data among different groups challenging.
- Insurance information illustrates the impacts of cost and healthcare coverage on access to medical aid in dying. Due to the Assisted Suicide Funding Restriction Act (ASFRA), many individuals reliant on federally funded insurance programs cannot use their insurance to cover the costs associated with medical aid in dying.
- Underlying Illness reports the most common illnesses and diagnoses for individuals who request medical aid in dying.

This report aggregates utilization information available in 2022. Although differences exist in how each jurisdiction collects and reports medical aid-in-dying data, key findings are analyzed below.

https://dchealth.dc.gov/sites/default/files/dc/sites/doh/page_content/attachments/Death%20With%20Dignity%20Act.FINAL_pdf

¹ Oregon Death with Dignity Act Annual Reports (1998-2021) Available from: https://www.oregon.gov/oha/ph/providerpartnerresources/evaluationresearch/deathwithdignityact/pages/ar-index.aspx

² Washington Death with Dignity Data (2009-2020). Available from: https://www.doh.wa.gov/YouandYourFamily/IllnessandDisease/DeathwithDignityAct/DeathwithDignityData

³ Vermont Report Concerning Patient Choice at the End of Life. (2017) Available from: https://www.healthvermont.gov/systems/end-of-life-decisions/patient-choice-and-control-end-life
Vermont Report Concerning Patient Choice at the End of Life. (2019) Available from: https://legislature.vermont.gov/assets/Legislative-Reports/2020-Patient-Choice-Legislative-Report-2.0.pdf

⁴ California End of Life Option Act Annual Report (2016-2021) Available from: https://www.cdph.ca.gov/Programs/CHSI/Pages/End-of-Life-Option-Act-aspx

⁵ Colorado End of Life Options Act Annual Report (2017-2021) Available from: https://www.colorado.gov/pacific/cdphe/medical-aid-dying

⁶ Hawai'i Our Care, Our Choice Act Annual Report (2019-2021) Available from: https://health.hawaii.gov/opppd/ococ/

⁷ District of Columbia Death with Dignity Act Annual Report. (2017-2018) Available from:

⁸ New Jersey Medical Aid in Dying for the Terminally III Act Data Summary (2019-2021) Available from: https://nj.gov/health/advancedirective/maid/

⁹ Maine Patient Directed Care at End Of Life Annual Report. (2021) Available from: https://legislature.maine.gov/doc/8664

Medical Aid-in-Dying Jurisdiction Usage Reports

Based on reported data, the following is known:

- > Cumulatively, for the past 20+ years across all jurisdictions, 6,378 people have used a medical aid in dying prescription to end their suffering.
- > Just over a third of people (37%) who go through the process and obtain the prescription never take it. However, they derive peace of mind simply from knowing they have the option if their suffering becomes too great. Less than 1% of the people who die in each jurisdiction use the law each year. 10
- > The majority of terminally ill people who use medical aid in dying more than 87% received hospice services at the time of their deaths, according to annual reports for which hospice data is available.
- > There is nearly equal use of medical aid in dying among men and women. There is no data on use of medical aid in dying by nonbinary people.
- > The rate at which Asian, Black, Hawaiian/Pacific Islander, Hispanic, Indigenous American/Alaskan Native, Latino/a/x (Hispanic) and multi-race people access and use prescriptions under medical aid-in-dying laws is consistently lower than with white populations.
- > Terminal cancer accounts for the vast majority of qualifying diagnoses, with neurodegenerative diseases such as ALS or Huntington's Disease following as the second-leading diagnosis.
- > Just over 90% of people who use medical aid in dying are able to die at home. According to various studies, that is the preference of most Americans. 11
- > Differences in data collection and reporting among jurisdictions do not allow for thorough comparisons of medical aid-in-dying use across the United States.

¹⁰ According to the Center for Disease Control, in 2019 in jurisdictions that authorized medical aid in dying, 427,296 people died in total. In 2019, authorized jurisdictions report 1,027 people died after being provided with a prescription for medical aid in dying – less than 0.002% of total deaths in 2019. Center for Disease Control, *Deaths: Final Data for 2019*, July 26, 2021, available from: https://stacks.cdc.gov/view/cdc/106058/cdc_106058_DS1.pdf

¹¹ Kaiser Family Foundation, *Views and Experiences with End-of-Life Medical Care in the U.S.*, April 27, 2017, available from: https://www.kff.org/report-section/views-and-experiences-with-end-of-life-medical-care-in-the-us-findings/

| Authorized Jurisdiction | OR | R (I) | V | /A | VT | (e) | С | A | С | 0 | D. | C. | HI | (0) | NJ | (b) | ME | (m) | Cumu | ulative |
|--|--------|--------|-------------|--------|---------|---------|---------|--------|--------|--------|------|--------|------|-------|-------|-------|-------|------|-------|---------|
| Data Period (a) | 1997 - | - 2021 | 2009 | - 2020 | 2013 - | - 2019 | 2016 - | - 2021 | 2017 - | - 2021 | 2017 | - 2018 | 2019 | -2021 | 2019- | -2021 | 2019- | 2021 | 1998 | - 2021 |
| Summary Da | ita | | | | | | | | | | | | | | | | | | | |
| People who received prescriptions (prescriptions written or filled) (b) (c) | 3,28 | 0 | 2,3 | 2,307 | | 15 | 3,287 | | 777 | | 4 | | 1; | 37 | N/A | | 11 | 8 | 10, | 025 |
| People who died after ingesting (d) | 2,15 | 9 | 1, <i>6</i> | b87 | 7 | 4 | 2,2 | 208 | N | ′A | 2 | | 76 | | 9 | 5 | 7 | 7 | 6,3 | 378 |
| Characteristi | ics | | | | | | | | | | | | | | | | | | | |
| Gender (g) | | | | | | | | | | | | | | | | | | | | |
| Female | 1,014 | 47% | 1,049 | 47.7% | | | 1,087 | 49.2% | 436 | 50.3% | 2 | 100% | 24 | 34.8% | 45 | 47.4% | | | 3,657 | 48.1% |
| Male | 1,145 | 53% | 1,151 | 52.3% | | | 1,113 | 50.4% | 430 | 49.7% | 0 | 0.0% | 44 | 63.8% | 50 | 52.6% | | | 3,933 | 51.8% |
| Unknown | 0 | 0.0% | 0 | 0.0% | | | 8 | 0.4% | 0 | 0.0% | 0 | 0.0% | 1 | 1.4% | 0 | 0.0% | | | 9 | 0.1% |
| Total | 2,159 | 100% | | 100% | | | 2,208 | 100% | 866 | 100% | 2 | 100% | 69 | 100% | 95 | 100% | | | 7,599 | 100% |
| Age Breakdov | | | | | Colorad | do, D.0 | C., and | Hawai | | | | | | | | | | | | |
| 18-54 | 172 | 8.0% | 163 | | | | | | 65 | 9% | 0 | 0.0% | 2 | | | | | | 402 | 7.8% |
| 55-64 | | | | 18.2% | | | | | 122 | 16.9% | 0 | 0.0% | | 14.5% | | | | | | 17.5% |
| 65-74 | | 30.4% | | 32.6% | | | | | | 31.3% | 1 | 50.0% | | 30.4% | | | | | | 31.5% |
| 75-84 | | | 529 | 24% | | | | | 187 | 25.9% | 1 | 50.0% | | 39.1% | | | | | 1,342 | |
| 85+ | 362 | 16.8% | 392 | 17.8% | | | | | 121 | 16.8% | 0 | 0.0% | 9 | 13% | | | | | 884 | 17.1% |
| Total | 2,159 | 100% | 2,205 | 100% | | | | | 721 | 100% | 2 | 100% | 69 | 100% | | | | | 5,156 | 100% |

| Authorized Jurisdiction | OR | 2 (1) | WA | | A VT (e) | | CA | | СО | | D.C. | | HI (o) | | NJ (p) | | ME | (m) | Cumu | ulative |
|--|--------|----------|-------|------|----------|--|-------|-------|-----|-------|------|------|--------|-------|--------|-------|----|-------|-------|---------|
| Age Breakdov | wn (Ca | lifornia |) | | | | | | | | | | | | | | | | | |
| Under 60 | | | | | | | 234 | 10.6% | | | | | | | | | | | 234 | 10.6% |
| 60-69 | | | | | | | 473 | 21.4% | | | | | | | | | | | 473 | 21.4% |
| 70-79 | | | | | | | 680 | 30.8% | | | | | | | | | | | 680 | 30.8% |
| 80-89 | | | | | | | 529 | 24% | | | | | | | | | | | 529 | 24% |
| 90+ | | | | | | | 292 | 13.2% | | | | | | | | | | | 292 | 13.2% |
| Total | | | | | | | 2,208 | 100% | | | | | | | | | | | 2,208 | 100% |
| Age Breakdov | wn (Ma | ine) | | | | | | | | | | | | | | | | | | |
| Under 65 | | | | | | | | | | | | | | | | | 10 | 14.7% | 10 | 14.7% |
| Over 65 | | | | | | | | | | | | | | | | | 58 | 85.3% | 58 | 85.3% |
| Total | | | | | | | | | | | | | | | | | 68 | 100% | 68 | 100% |
| Race/Ethnicity | y (h) | | | | | | | | | | | | | | | | | | | |
| Asian | 32 | 1.5% | 0 | 0% | | | 144 | 6.5% | 13 | 1.8% | 0 | 0.0% | 13 | 18.8% | 4 | 4.2% | | | 206 | 2.7% |
| Black | 1 | 0.0% | 14 | 1% | | | 21 | 0.9% | 3 | 0.4% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | | | 39 | 0.5% |
| Hawaiian / Pacific Islander | 1 | 0.0% | | | | | 2 | 0.1% | | | | | 5 | 7.2% | | | | | 8 | 0.1% |
| Hispanic and/or nonwhite (WA) | | | 32 | 1.5% | | | | | | | | | | | | | | | 32 | 0.4% |
| Indigenous American / Alaskan Native | 3 | 0.1% | | | | | 0 | 0.0% | | | | | 0 | 0.0% | | | | | 3 | 0.0% |
| Latino/a/x (Hispanic) | 28 | 1.3% | | | | | 89 | 4% | 22 | 3.1% | 0 | 0.0% | 2 | 2.9% | 0 | 0.0% | | | 141 | 1.9% |
| Multi-Race (Two or more races) | 8 | 0.4% | | | | | 12 | 0.5% | | | 0 | 0.0% | 3 | 4.35% | 0 | 0 | | | 23 | 0.3% |
| Other / Unknown | 11 | 0.5% | 62 | 2.8% | | | 13 | 0.6% | 1 | 0.1% | 0 | 0.0% | 2 | 2.9% | 2 | 2.1% | | | 91 | 1.2% |
| White | 2,075 | 96.1% | 2,068 | 95% | | | 1,945 | 87.4% | 682 | 94.6% | 2 | 100% | 44 | 63.8% | 89 | 93.7% | 49 | 100.% | 6,954 | 92.8% |
| Total | 2,159 | 100% | 2,176 | 100% | | | 2,226 | 100% | 721 | 100% | 2 | 100% | 69 | 100% | 95 | 100% | 49 | 100% | 7,497 | 100% |

| Authorized Jurisdiction | OF | R (I) | V\ | WA | | (e) | CA | | CO | | D.C. | | HI (o) | | NJ <mark>(p)</mark> | | ME (m) | | Cumu | ılative |
|--|--------|-------|-------|-------|--|-----|-------|-------|-----|-------|------|-------|--------|-------|---------------------|-------|--------|--|-------|---------|
| Education (i) (| j) (q) | | | | | | | | | | | | | | | | | | | |
| High School Diploma or GED or Less | 575 | 26.6% | 557 | 25.6% | | | 510 | 23.1% | 174 | 24.1% | 0 | 0.0% | 10 | 14.5% | 19 | 20% | | | 1,845 | 24.8% |
| Some College | 435 | 20.1% | 886 | 40.7% | | | 373 | 16.9% | 98 | 13.6% | 1 | 50.0% | 6 | 8.7% | 9 | 9.5% | | | 1,808 | 24.3% |
| Associate's Degree, Bachelor's Degree, Master's Degree, Doctorate or Professional Degree | 1,130 | 52.3% | 713 | 32.8% | | | 1,301 | 58.9% | 447 | 62% | 1 | 50.0% | 28 | 40.6% | 67 | 70.5% | | | 3,687 | 49.6% |
| Unknown | 19 | 0.9% | 20 | 0.9% | | | 24 | 1.1% | 2 | 0.3% | 0 | 0.0% | 25 | 36.2% | 0 | 0.0% | | | 90 | 1.2% |
| Total | 2,159 | 100% | 2,176 | 100% | | | 2,208 | 100% | 721 | 100% | 2 | 100% | 69 | 100% | 95 | 100% | | | 7,430 | 100% |
| Marital Status | ; | | | | | | | | | | | | | | | | | | | |
| Married (Including Registered Domestic Partner) | | 46.0% | - | 47.3% | | | | | | 46.2% | | | | | | 51.6% | | | | 46.7% |
| Widowed | | 21.7% | 420 | | | | | | 138 | 19.1% | | | | | | 23.2% | | | | 20.4% |
| Divorced | 507 | 23.5% | 544 | 25% | | | | | 195 | 27% | | | | | 14 | 14.7% | | | 1,260 | 24.5% |
| Never Married, Single, Other, Unknown | 190 | 8.8% | 182 | 8.4% | | | | | 55 | 7.6% | | | | | 10 | 10.5% | | | 437 | 8.5% |
| Total | 2,159 | 100% | 2,174 | 100% | | | | | 721 | 100% | | | | | 95 | 100% | | | 5,149 | 100% |

| Authorized Jurisdiction | OF | R (I) | V | /A | VT | (e) | С | A | C | Э | D. | C. | HI | (0) | NJ (| (p) | ME | (m) | Cumu | ulative |
|--|-------|-------|-------|-------|----|-----|-------|-------|-----|-------|----|------|----|-------|------|-----|----|-----|-------|---------|
| Hospice Care | | | | | | | | | | | | | | | | | | | | |
| Enrolled | 1,945 | 90.1% | 1,010 | 83.1% | | | 1,926 | 87.2% | 612 | 84.9% | | | 19 | 82.6% | | | | | 5,512 | 87.1% |
| Not Enrolled | 180 | 8.3% | 151 | 12.4% | | | 214 | 9.7% | | | | | 0 | 0.0% | | | | | 545 | 8.6% |
| Unknown | 34 | 1.6% | 54 | 4.4% | | | 68 | 3.1% | 1 | 0.1% | | | 4 | 17.4% | | | | | 161 | 2.5% |
| Not under hospice care or unknown (Colorado) | | | | | | | | | 108 | 15% | | | | | | | | | 108 | 1.7% |
| Total | 2,159 | 100% | 1,215 | 100% | | | 2,208 | 100% | 721 | 100% | | | 23 | 100% | | | | | 6,326 | 100% |
| Insurance (f) | | | | | | | | | | | | | | | | | | | | |
| Private | 804 | 37.2% | 296 | 14.3% | | | 309 | 14% | | | 2 | 100% | 11 | 15.9% | | | | | 1,422 | 22.5% |
| Medicare, Medicaid or other governmental | 1,076 | 49.8% | 774 | 37.5% | | | 322 | 14.6% | | | 0 | 0.0% | 26 | 37.7% | | | | | 2,198 | 34.8% |
| Medicare with another type of insurance (unspecified) (California) | | | | | | | 1,058 | 47.9% | | | | | | | | | | | 1,058 | 16.8% |
| Combination of private and Medicare/Med icaid | | | 196 | 9.5% | | | 56 | 2.5% | | | 0 | 0.0% | 17 | 24.6% | | | | | 269 | 4.3% |
| Insured (unspecified) | | | 246 | 11.9% | | | 196 | 8.9% | | | | | | | | | | | 246 | 3.9% |
| None, Other Unknown | 279 | 12.9% | 554 | 26.8% | | | 267 | 12.1% | | | 0 | 0.0% | 15 | 21.7% | | | | | 1,115 | 17.7% |
| Total | 2,159 | 100% | 2,066 | 100% | | | 2,208 | 91.1% | | | 2 | 100% | 69 | 100% | | | | | 6,308 | 100% |

| Authorized Jurisdiction | OR (I) | | WA | | VT (e) | | CA | | С | СО | | D.C. | | (0) | NJ (p) | | ME (m) | | Cumu | ılative |
|---|-----------------------|---------|-------|--------|----------|--------|---------|---------|---------|-------|---|------|----|-------|--------|-------|--------|-------|-------|---------|
| Underlying Illı | ness (<mark>n</mark> | | | | | | | | | | | | | | | | | | | |
| Malignant Neoplasms (Cancer) | 1,566 | 72.5% | 1,565 | 74.5% | 88 | 76.5% | 1,493 | 67.6% | 491 | 62.5% | 4 | 100% | 51 | 72.9% | 56 | 69.5% | 47 | 69.1% | 5,371 | 70.6% |
| Neurological Disease | 242 | 11.2% | 199 | 9.5% | 19 | 16.5% | 260 | 11.8% | 139 | 17.7% | 0 | 0.0% | 7 | 10% | 18 | 18.9% | 9 | 13.2% | 893 | 11.7% |
| Respiratory Disease (e.g., COPD) | 123 | 5.7% | 134 | 6.4% | 0 | 0.0% | 142 | 6.4% | 43 | 5.5% | 0 | 0.0% | 6 | 8.6% | 4 | 4.2% | 4 | 5.9% | 456 | 6% |
| Heart/ Circulatory Disease/ Cardiovascular | 134 | 6.2% | 115 | 5.5% | 0 | 0.0% | 169 | 7.7% | 56 | 7.1% | 0 | 0.0% | 4 | 5.7% | 3 | 3.2% | 3 | 4.4% | 484 | 6.4% |
| Other Illnesses | 94 | 4.4% | 88 | 4.2% | 8 | 7.0% | 144 | 6.5% | 57 | 7.3% | 0 | 0.0% | 2 | 2.9% | 4 | 4.2% | 5 | 7.4% | 402 | 5.3% |
| Total | 2,159 | 100% | 2,101 | 100% | 115 | 100% | 2,208 | 100% | 786 | 100% | 4 | 100% | 70 | 100% | 95 | 100% | 68 | 100% | 7,606 | 100% |
| Place of Death | n / Loc | ation V | Vhere | Medica | ation Ir | gested | d / Loc | ation o | f Patie | nt | | | | | | | | | | |
| Home / Private Home / Residence | 1,999 | 92.6% | 1,069 | 88.0% | | | 1,575 | 91.4% | 606 | 85% | | | | | 88 | 92.6% | | | 5,337 | 90.4% |
| Assisted-Living Residence / Nursing Home / Long-Term Care | 122 | 5.7% | 99 | 8.1% | | | 116 | 6.7% | 56 | 7.9% | | | | | 4 | 4.2% | | | 397 | 6.7% |
| Inpatient Hospice Residence | 3 | 0.1% | 0 | 0.0% | | | 23 | 1.3% | 20 | 2.8% | | | | | 0 | 0.0% | | | 46 | 0.8% |
| Hospital / Other / Unknown | 35 | 1.6% | 47 | 3.9% | | | 9 | 0.5% | 31 | 4.3% | | | | | 3 | 3.2% | | | 125 | 2.1% |
| Total | 2,159 | 100% | 1,215 | 100% | | | 1,723 | 100% | 713 | 100% | | | | | 95 | 100% | | | 5,905 | 100% |

| Authorized Jurisdiction | OF | OR (I) | | WA | | VT (e) | | CA | | со | | D.C. | | (o) | NJ (p) | | ME (m) | | Cumu | ılative |
|--|--------|--------|--------|---------|-------|----------|--------|-------|--|----|--|------|--|-----|--------|--|--------|--|-------|---------|
| Physician or T | rained | Health | care P | rovider | Prese | nt at In | gestio | n | | | | | | | | | | | | |
| Prescribing Physician | 332 | 15.9% | 80 | 6.6% | | | 0 | 0.0% | | | | | | | | | | | 412 | 8.2% |
| Attending Physician | 0 | 0.0% | 0 | 0.0% | | | 418 | 24.3% | | | | | | | | | | | 418 | 8.3% |
| Other Physician | 0 | 0.0% | 0 | 0.0% | | | 58 | 3.4% | | | | | | | | | | | 58 | 1.2% |
| Other Provider / Healthcare Provider | 469 | 22.5% | 715 | 58.8% | | | 292 | 16.9% | | | | | | | | | | | 1,476 | 29.4% |
| Volunteer | 148 | 7.1% | n/a | n/a | | | n/a | n/a | | | | | | | | | | | 148 | 2.9% |
| No Provider/Volunteer | 198 | 9.5% | 224 | 18.4% | | | 207 | 12.0% | | | | | | | | | | | 629 | 12.5% |
| Unknown | 940 | 45% | 196 | 16.1% | | | 748 | 43.4% | | | | | | | | | | | 1,884 | 37.5% |
| Total | 2,087 | 100% | 1,215 | 100% | | | 1,723 | 100% | | | | | | | | | | | 5,025 | 100% |

Table Notes

- (a) Data Period California: The first California annual report detailed the first six months of the law's implementation; for some data points, data is only available from 2018.
- (b) Prescriptions Washington: Washington only reports the number of prescriptions dispensed. To obtain a minimum aggregate count across all jurisdictions, across all years, we assumed that a prescription had to have been written in order to then be dispensed. It is possible that more prescriptions were written.
- (c) Death Certificates Colorado: It is important to note that these statistics reflect all deaths identified among individuals prescribed aid-in-dying medication, whether or not they used the medication, and irrespective of whether their death followed ingestion of medication or was caused by the underlying terminal illness or condition, or some other cause.
- (d) Died After Ingestion California: The cumulative counts reported do not match prior reports (and thus do not match the latter totals shown). These differences arise from a number of factors including the timing of forms received, the registration of deaths and the inclusion of duplicate records, which have been removed.
- (e) Vermont: Vermont does not report complete data. Data on 34 patients is missing.
- (f) Insurance California: California: California reports insurance metrics uniquely. "Medicare/Medicaid with another type of unspecified insurance" is used for this aggregate report. "Unspecified insurance" may include private or public insurance; there is no way to differentiate.
- (g) Gender: The way that the categories are defined excludes transgender and nonbinary individuals. All jurisdictions that have reportable data do so in categories of only male and female. Data would be more accurate if gender identity were fully included. The data reflects what the jurisdiction has reported.
- (h) Racial/Ethnic Demographics: Washington state and Colorado use inconsistent racial/ethnic categories. Accordingly, to accurately aggregate data across all years, Washington's terminology "Hispanic and/or non-white" is used specifically for Washington. In Colorado, "white-Hispanic" is recorded as "Latinx (Hispanic)."
- (i) Education: Where certain jurisdictions reported more specific categories, to remain consistent across all jurisdictions and all years, combined categories include (1) "high school diploma or GED or less" and (2) "Associate's Degree, Bachelor's Degree, Master's Degree, Doctorate or Professional Degree."
- (j) Education Oregon: For Oregon's data from 1998-2002, "high school grad./some college" is included as "high school diploma or GED or less."
- (k) Age Breakdown Oregon: Oregon's data from 2005 uses a different age breakdown than other years. To remain consistent with other jurisdictions and years, "18-44" is reported under "18-54," "45-65" under "55-65," and "65-84" under "75-84."
- (I) Incomplete Data: Not all data forms and documentation of death were returned to the state of Oregon and New Jersey prior to the publishing of the 2022 report. Further, some individuals will receive their prescription later in a previous calendar year but not ingest the medication until the next calendar year. Accordingly, when the updated information is released, it will be included in subsequent reports.
- (m) Maine: Though Maine released more data than what is contained in this spreadsheet, the way they collected and presented some data was incompatible with aggregating methods and has been left out. Rather than releasing total sums, for the vast majority of categories Maine provided percentages, which cannot be used to accurately discern the total numbers in any given category.
- (n) Hawai'i Underlying Illness: In 2021, one patient in Hawai'i had an underlying illness of both COPD and cancer. Accordingly, that patient is counted twice in this spreadsheet in the category of underlying illness.
- (o) Hawai'i 2021 Data: For 2021, the state of Hawai'i reports that 32 people died from medical-aid-in-dying medication; however, the state only provides data on 26 of those 32 patients.
- (p) Incomplete Data: Not all data forms and documentation of death were returned to New Jersey prior to the publishing of the 2022 report. Further, some individuals will receive their prescription later in a previous calendar year but not ingest the medication until the next calendar year. Accordingly, when the updated information is released, this report will be updated.
- (g) Washington Education: For 2021, "some college" also includes patients holding collegiate degrees or higher.
- (r) N/A vs 0: "N/A" is used to designate categories wherein the jurisdiction does not report on that categorization. "0" is used to show that the jurisdiction does report that category but had nothing to report for that specific year.